|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2005
Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease
1 Centre des Maladies Vasculaires Pulmonaires, UPRES EA2705, Service de Pneumologie et Réanimation respiratoire, Hôpital Antoine-Béclère, Université Paris-Sud, and 2 Service de Virologie, Hôpital Pitié-Salpétrière, and 3 Service des Maladies Infectieuses, and 4 Service d'Hématologie, and 5 Service d'Anatomie Pathologique, Groupe hospitalier Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France.
CORRESPONDENCE: M. Humbert, Centre des Maladies Vasculaires Pulmonaires, UPRES EA 2705, Service de Pneumologie et Réanimation Respiratoire, Hôpital Antoine Béclère, Assistance Publique-Hôpitaux de Paris, Université Paris-Sud, 157 rue de la Porte de Trivaux, 92140 Clamart, France. Fax: 33 146303824. E-mail: marc.humbert{at}abc.ap-hop-paris.fr
Keywords: Castleman's disease, HIV, human herpes virus 8, pulmonary arterial hypertension
Received: November 23, 2004
Accepted April 26, 2005
The present study describes a case of pulmonary arterial hypertension (PAH) associated with multicentric Castleman's disease in a patient infected with HIV type 1 and human herpes virus 8.
Therapy included highly active antiretroviral therapy, warfarin, diuretics, continuous i.v. epoprostenol and 12-monthly pulses of cyclophosphamide.
The patient's condition improved dramatically with complete reversibility of PAH, allowing weaning of continuous i.v. epoprostenol therapy. After 5 yrs, both Castleman's disease and PAH have not relapsed. This supports the hypothesis that control of inflammation and retroviral replication may be of interest in the context of PAH, complicating the course of an inflammatory condition associated with viral infection.
In conclusion, further studies should help in characterising the best candidates for anti-inflammatory treatment in the setting of pulmonary arterial hypertension.
This article has been cited by other articles:
|
|
 |
|
  S. Ocak, F. Feoli, J. Fastrez, D. Butenda, C. Litvine, I. M. Colin, and J-P d'Odemont Pulmonary arterial hypertension in a patient with stage II sarcoidosis and Hashitoxicosis Eur. Respir. Rev., June 1, 2009; 18(112): 125 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Degano, A. Yaici, J. Le Pavec, L. Savale, X. Jais, B. Camara, M. Humbert, G. Simonneau, and O. Sitbon Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension Eur. Respir. J., January 1, 2009; 33(1): 92 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Bull, C. A. Meadows, C. D. Coldren, M. Moore, S. M. Sotto-Santiago, S. P. Nana-Sinkam, T. B. Campbell, and M. W. Geraci Human Herpesvirus-8 Infection of Primary Pulmonary Microvascular Endothelial Cells Am. J. Respir. Cell Mol. Biol., December 1, 2008; 39(6): 706 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Perros, P. Dorfmuller, R. Souza, I. Durand-Gasselin, V. Godot, F. Capel, S. Adnot, S. Eddahibi, M. Mazmanian, E. Fadel, et al. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension Eur. Respir. J., May 1, 2007; 29(5): 937 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Perros, P. Dorfmuller, R. Souza, I. Durand-Gasselin, S. Mussot, M. Mazmanian, P. Herve, D. Emilie, G. Simonneau, and M. Humbert Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension Eur. Respir. J., March 1, 2007; 29(3): 462 - 468. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |